Extract
Pulmonary hypertension (PH) is a common complication of many chronic lung diseases, especially COPD and interstitial lung disease (ILD) [1]. In these conditions, the development of PH is associated with an aggravation of symptoms and an increase in mortality risk. In most patients with chronic lung disease, the haemodynamic severity of PH is mild to moderate, while some patients develop severe PH, which is presently defined by a mean pulmonary arterial pressure (mPAP) ≥35 mmHg or mPAP ≥25 mmHg in the presence of a cardiac index <2.0 L·min−1·m−2 [2]. These haemodynamic criteria were introduced per expert consensus but were not based on solid data.
Abstract
In patients with pulmonary hypertension associated with interstitial lung disease, pulmonary vascular resistance provides stronger prognostic information than mean pulmonary arterial pressure https://bit.ly/3w1QcIS
Acknowledgements
The authors are indebted to the COMPERA investigators and their co-workers.
Footnotes
This article has an editorial commentary: https://doi.org/10.1183/13993003.02008-2021
Conflict of interest: K.M. Olsson has received fees for lectures and/or consultations from Actelion, Bayer, Janssen, MSD, United Therapeutics, GSK and Pfizer.
Conflict of interest: M.M. Hoeper has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, GSK, Janssen, MSD and Pfizer.
Conflict of interest: C. Pausch has no disclosures.
Conflict of interest: E. Grünig received fees for lectures and/or consultations from Actelion, Bayer, GSK, Janssen, MSD, United Therapeutics and Pfizer.
Conflict of interest: D. Huscher has received fees for lectures and consultations from Actelion.
Conflict of interest: D. Pittrow has received fees for consultations from Actelion, Biogen, Amgen, Aspen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Viatris, Takeda and Sanofi.
Conflict of interest: S. Rosenkranz has received fees for lectures and/or consultations from Abbott, Acceleron, Actelion, Bayer, BMS, Gilead, GSK, Janssen, Pfizer, MSD, Novartis, United Therapeutics and Vifor.
Conflict of interest: H. Gall reports personal fees for lectures and/or consultations from Actelion, AstraZeneca, Bayer, BMS, Gilead, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer, and United Therapeutics.
Support statement: This work was supported by the German Centre of Lung Research (DZL). COMPERA is funded by unrestricted grants from Acceleron, Bayer, GSK, Janssen and OMT. These companies were not involved in data analysis or the writing of this manuscript. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received May 25, 2021.
- Accepted June 17, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org